EBOLA IN THE US: PATIENT NOW RECEIVING EXPERIMENTAL TREATMENT Thomas Eric Duncan, the first patient to be diagnosed with Ebola in the United States, is now receiving an experimental drug called brincidofovir. The drug is made by Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need. Emergency Investigational New Drug Applications (EIND) were granted by the U.S. Food and Drug Administration (FDA). Based on in vitro data from work conducted by the CDC and the National Institutes of Health (NIH) suggesting brincidofovirs activity against Ebola, we are hopeful that brincidofovir may offer a potential treatment for Ebola Virus Disease during this outbreak,” said Michelle Berry, MD, MPH, President and CEO of Chimerix. Chimerix is working closely with the FDA to finalize a clinical trial protocol early this week to assess the safety, tolerability, and efficacy of brincidofovir in patients who are confirmed to have an infection with the Ebola virus. Testing at the Viral Special Pathogens Branch of the CDC and the NIH revealed in vitro activity of brincidofovir against the Ebola virus that was similar to that seen in in vitro assessments of brincidofovir against other viral diseases, such as adenovirus and smallpox. Additional tests of brincidofovir in in vivo (animal) models of Ebola virus infection are currently underway.
Posted on: Mon, 06 Oct 2014 21:50:57 +0000
Trending Topics
Recently Viewed Topics
© 2015